Krystal Biotech (NASDAQ:KRYS) Cut to “Hold” at BidaskClub

BidaskClub cut shares of Krystal Biotech (NASDAQ:KRYS) from a buy rating to a hold rating in a research note published on Thursday, BidAskClub reports.

Several other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Krystal Biotech from a buy rating to a hold rating in a research note on Wednesday, July 24th. ValuEngine downgraded shares of Krystal Biotech from a strong-buy rating to a buy rating in a research note on Friday, August 2nd. Guggenheim raised their price objective on shares of Krystal Biotech from $48.00 to $73.00 and gave the stock a buy rating in a research note on Tuesday, June 25th. William Blair reissued a buy rating on shares of Krystal Biotech in a research note on Monday, June 24th. Finally, Chardan Capital raised their price objective on shares of Krystal Biotech from $57.50 to $75.00 and gave the stock a buy rating in a research note on Monday, June 24th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $59.20.

Shares of NASDAQ KRYS opened at $42.66 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 49.80 and a quick ratio of 49.80. Krystal Biotech has a 1 year low of $14.30 and a 1 year high of $51.67. The firm has a 50-day simple moving average of $45.52 and a two-hundred day simple moving average of $33.00.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). On average, sell-side analysts expect that Krystal Biotech will post -1.47 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in shares of Krystal Biotech by 204.8% during the second quarter. Price T Rowe Associates Inc. MD now owns 927,079 shares of the company’s stock worth $37,333,000 after acquiring an additional 622,959 shares during the period. Orbimed Advisors LLC increased its position in shares of Krystal Biotech by 984.3% during the second quarter. Orbimed Advisors LLC now owns 642,006 shares of the company’s stock worth $25,854,000 after acquiring an additional 582,796 shares during the period. BlackRock Inc. increased its position in shares of Krystal Biotech by 989.8% during the second quarter. BlackRock Inc. now owns 601,514 shares of the company’s stock worth $24,224,000 after acquiring an additional 546,317 shares during the period. Citadel Advisors LLC increased its position in shares of Krystal Biotech by 54.0% during the second quarter. Citadel Advisors LLC now owns 497,170 shares of the company’s stock worth $20,021,000 after acquiring an additional 174,296 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Krystal Biotech by 40.6% during the second quarter. Vanguard Group Inc. now owns 496,879 shares of the company’s stock worth $20,009,000 after acquiring an additional 143,409 shares during the period. 38.59% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Featured Article: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.